 |
|
|
| |
- VALUE OF "NEW" AUTOANTIBODY TESTING IN THE DIFFERENTIAL DIAGNOSIS OF AUTOIMMUNE LIVER CONDITIONS
P. Milkiewicz1, H.B. Buwaneswaran1, L. Lee2, C. Coltescu1, Z. Shums2, G.L. Norman2, E.J. Heathcote1 University of Toronto, Toronto, Canada1, INOVA Diagnostics, San Diego, CA2
- ENHANCED DETECTION AND CHARACTERIZATION OF PRIMARY BILIARY CIRRHOSIS PATIENTS WITH NEW M2 EP(MIT3), gp210, AND sp100 ELISA ASSAYS
Gary L. Norman1, Lesley Lee1, Zakera Shums1, Dimitrios-Petrou Bogdanos2, Howard J. Worman3, Edward L. Krawitt4, Patrick Leung5, Chris Aoki5, Diego Vergani2, M. Eric Gershwin5; 1INOVA Diagnostics, San Diego, CA; 2Institute of Liver Studies, Kings College Hospital, London, UK, 3Columbia University, NY, NY, 4 Univ. of Vermont, Burlington, VT., 5 Univ. of California, Davis, CA.
- DETECTION OF MULTIPLE PRIMARY BILIARY CIRRHOSIS-SPECIFIC AUTOANTIBODIES BY A NEW MULTIANALYTE, DUAL ISOTYPE PBC SCREEN IgG/IgA ELISA
Zakera Shums1 Dimitrios-Petrou Bogdanos2, E. Jenny Heathcote3, Piotr Milkiewicz3, M. Eric Gershwin4, Howard J. Worman5, Diego Vergani2, Gary L. Norman1; 1INOVA Diagnostics, San Diego, CA; 2Institute of Liver Studies, Kings College Hospital, London, UK, 3Univ. of Toronto, Toronto,Canada, 4Univ. of California, Davis, CA., 5Columbia Univ. NY, NY,
- THE PREVALENCE OF PBC-SPECIFIC AUTOANTIBODIES IN PATIENTS WITH SYSTEMIC SCLEROSIS
Andrzej Bialek1, Susan Encabo2, Beata Butkiewicz3, Anna Wiechowska-Kozlowska1, Marek Brzosko3, Zakera Shums2, Gary L. Norman2, Piotr Milkiewicz4 Div. Gastroenterology1, Rheumatology3, & Liver Unit4, Pomeranian Medical School, Szczecin, Poland; INOVA Diagnostics2, San Diego, CA
- A NEW ELISA SIMULTANEOUSLY DETECTS PRIMARY BILIARY CIRRHOSIS SPECIFIC MITOCHONDRIAL AND NUCLEAR AUTOANTIBODIES
C. Liaskos1, G.L. Norman2, P. Papamichalis1, A. Garagounis1, Z. Shums2,
- DETECTION OF LIVER-KIDNEY MICROSOMAL (LKM-1) ANTIBODIES BY A NEW HUMAN CYTOCHROME P4502D6 ELISA
Gary L. Norman, Zakera Gandhi, Tiffany Crowther, Walter L. Binder, Rene Humbel1, and James Goeken2 INOVA Diagnostics, San Diego, CA; 1Lab. Biochemie-Immunopathologie, Centre Hospitalier de Luxembourg; 2Immunopathology Lab., University of Iowa
- SOLUBLE LIVER ANTIGEN (SLA) ANTIBODY DETECTION BY ELISA AND MULTIPLEXING TECHNOLOGIES
Zakera Gandhi1, Ansgar W. Lohse2, Johannes Herkel2, Gary L. Norman1, 1INOVA Diagnostics, San Diego,CA; 2Johannes Gutenberg University,Mainz,Germany.
- DETECTION OF SMOOTH MUSCLE ANTIBODIES USING THE QUANTA™ Lite ACTIN ELISA
W. Binder, V. Nelson, and S. Lewis, INOVA Diagnostics, Inc. San Diego, CA
- DETECTION OF AUTOANTIBODIES TO sp100 IN PRIMARY BILIARY CIRRHOSIS PATIENTS BY A NEW ELISA
Gary L. Norman1, Zakera Shums1, Dimitrios-Petrou Bogdanos2, Howard J. Worman3, Carol L. Peebles1, Lesley Lee1, Andrew J. Lassen1, Carlos von Mühlen4, Edward L. Krawitt5, Diego Vergani2 , 1INOVA Diagnostics, San Diego, CA; 2Institute of Liver Studies, Kings College Hospital, London, UK, 3Columbia University, New York, NY, 4Hospital Sao Lucas, Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Brazil, 5University of Vermont, Burlington, VT.
- DETECTION OF AUTOANTIBODIES TO THE NUCLEAR PORE COMPLEX gp210 IN PRIMARY BILIARY CIRRHOSIS PATIENTS BY A NEW ELISA
Gary L. Norman1, Zakera Shums1, Carol L. Peebles1, Kiyomitsu Miyachi2, Raleigh W Hankins2, Minoru Shibata3, Etsuko Hashimoto4, Hiroshi Miyakawa5, Eng M Tan6, 1INOVA Diagnostics, San Diego, CA; 2Health Science Research Institute Yokohama, Japan, 3Kanto Medical Center,Tokyo, Japan; 4Tokyo Women's Medical College, Tokyo, Japan 5Teikyo University, Kanagawa,Japan, 6Scripps Research Institute, La Jolla, CA.
- ANTI-gp210 ANTIBODY IN COMBINATION WITH ANTI-CENTROMERE ANTIBODY MAY IDENTIFY PBC PATIENTS WHO ARE AT HIGH RISK FOR END-STAGE HEPATIC FAILURE
Minoru Nakamura1 Yasushi Takii1,Tsuyoshi Mori1, Atsumasa Komori1, Terufumi Yokoyama1, Manabu Daikoku1, Takehiro Matsumoto1, Kiyoshi Migita1, Hiroshi Yatsuhashi1, Hiromi Ishibash1, Naohiko Masaki2, Hiroshi Adachi2, Yukio Watanabe2, Yoko Nakamura2, Eeichi Takezaki2, Hideharu Harada2, Takehiro Sando2, Takeo Saoshiro2, Tatsuji Komatsu2, Masaaki Shimada2, Shigeki Hayashi2, Masakazu Kobayashi2, Takeshi Sodeyama2, Toyokichi Muro2, Akihide Masumoto2, Kazuhiro Sugi2, Lesley Lee3, Zakera Shums3, Gary L. Norman3; 1Clinical Research Center, NHO Nagasaki Medical Center and Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Omura, Japan, 2National Hospital Organization Study Group for Liver disease in Japan(NHOSLJ), 3INOVA Diagnostics, San Diego, CA.
|
| |
|
|
|
|
|
